Inmune Bio (INMB) Accumulated Expenses (2022 - 2026)

Inmune Bio has reported Accumulated Expenses for 5 years, with the latest figure at $25000.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 75.73% year-over-year to $25000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25000.0 (down 75.73% YoY) and the FY2025 annual result came in at $25000.0, changed 0.0% from the prior year.
• Accumulated Expenses steadied at $25000.0 in Q1 2026 per INMB's latest filing, from $25000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $184000.0 in Q2 2025 and troughed at $9000.0 in Q4 2022.
• A 5-year average of $55571.4 and a median of $30000.0 in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2026: Accumulated Expenses surged 1444.44% in 2024, then sank 75.73% in 2026.
• Over 5 years, Accumulated Expenses stood at $9000.0 in 2022, then jumped by 288.89% to $35000.0 in 2023, then retreated by 28.57% to $25000.0 in 2024, then changed by 0.0% to $25000.0 in 2025, then changed by 0.0% to $25000.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $25000.0, $25000.0, and $25000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.